IN2015KN00375A - - Google Patents
Info
- Publication number
- IN2015KN00375A IN2015KN00375A IN375KON2015A IN2015KN00375A IN 2015KN00375 A IN2015KN00375 A IN 2015KN00375A IN 375KON2015 A IN375KON2015 A IN 375KON2015A IN 2015KN00375 A IN2015KN00375 A IN 2015KN00375A
- Authority
- IN
- India
- Prior art keywords
- cancer patient
- lipoplatin
- patient
- administered
- chemotherapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/050630 WO2014027996A1 (en) | 2012-08-13 | 2012-08-13 | Improved methods for treating cancer with reduced renal toxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015KN00375A true IN2015KN00375A (zh) | 2015-07-10 |
Family
ID=50101360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN375KON2015 IN2015KN00375A (zh) | 2012-08-13 | 2012-08-13 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150258140A1 (zh) |
| EP (1) | EP2882420A4 (zh) |
| JP (1) | JP2015528446A (zh) |
| CN (1) | CN104736143A (zh) |
| AU (1) | AU2012387681A1 (zh) |
| BR (1) | BR112015003111A2 (zh) |
| CA (1) | CA2882156A1 (zh) |
| EA (1) | EA201590325A1 (zh) |
| IN (1) | IN2015KN00375A (zh) |
| MA (1) | MA37931A1 (zh) |
| SG (1) | SG11201501146VA (zh) |
| WO (1) | WO2014027996A1 (zh) |
| ZA (1) | ZA201501123B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2873214C (en) * | 2012-05-11 | 2021-02-16 | Reset Therapeutics, Inc. | Carbazole-containing sulfonamides as cryptochrome modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04169531A (ja) * | 1990-11-01 | 1992-06-17 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金錯体を含有するリポソーム製剤 |
| JPH04169532A (ja) * | 1990-11-01 | 1992-06-17 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金錯体含有リポソーム製剤 |
| EP0551169A1 (en) * | 1992-01-10 | 1993-07-14 | Takeda Chemical Industries, Ltd. | Liposome composition and production thereof |
| ES2208946T3 (es) * | 1996-08-23 | 2004-06-16 | Sequus Pharmaceuticals, Inc. | Liposomas que contienen un compuesto de cisplatino. |
| DE19954613A1 (de) * | 1999-11-12 | 2001-05-17 | Enthone Omi Deutschland Gmbh | Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| GR20060100144A (el) * | 2006-03-03 | 2007-10-17 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene | |
| EP2123258A1 (en) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
| WO2010148163A1 (en) * | 2009-06-18 | 2010-12-23 | University Of Utah Research Foundation | Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy |
-
2012
- 2012-08-12 MA MA37931A patent/MA37931A1/fr unknown
- 2012-08-13 JP JP2015527429A patent/JP2015528446A/ja active Pending
- 2012-08-13 WO PCT/US2012/050630 patent/WO2014027996A1/en active Application Filing
- 2012-08-13 EP EP12883054.4A patent/EP2882420A4/en not_active Withdrawn
- 2012-08-13 IN IN375KON2015 patent/IN2015KN00375A/en unknown
- 2012-08-13 BR BR112015003111A patent/BR112015003111A2/pt not_active IP Right Cessation
- 2012-08-13 US US14/421,392 patent/US20150258140A1/en not_active Abandoned
- 2012-08-13 AU AU2012387681A patent/AU2012387681A1/en not_active Abandoned
- 2012-08-13 SG SG11201501146VA patent/SG11201501146VA/en unknown
- 2012-08-13 EA EA201590325A patent/EA201590325A1/ru unknown
- 2012-08-13 CN CN201280075225.2A patent/CN104736143A/zh active Pending
- 2012-08-13 CA CA2882156A patent/CA2882156A1/en not_active Abandoned
-
2015
- 2015-02-18 ZA ZA2015/01123A patent/ZA201501123B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2882420A4 (en) | 2016-06-01 |
| AU2012387681A1 (en) | 2015-03-05 |
| WO2014027996A1 (en) | 2014-02-20 |
| EP2882420A1 (en) | 2015-06-17 |
| ZA201501123B (en) | 2020-02-26 |
| SG11201501146VA (en) | 2015-05-28 |
| CA2882156A1 (en) | 2014-02-20 |
| MA37931A1 (fr) | 2016-07-29 |
| US20150258140A1 (en) | 2015-09-17 |
| BR112015003111A2 (pt) | 2017-10-10 |
| EA201590325A1 (ru) | 2015-09-30 |
| CN104736143A (zh) | 2015-06-24 |
| JP2015528446A (ja) | 2015-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| PH12017501500A1 (en) | Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy | |
| MX2015014596A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
| PH12014502046B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| MY196418A (en) | Therapeutically Active Compounds and Their Methods of use | |
| PH12014502029B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| NZ702469A (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
| MD20160016A2 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| MX2020012924A (es) | Terapias combinadas de coenzima q10 para el tratamiento de cancer. | |
| MX2015002669A (es) | Metodos de administracion de tratamiento con pirfenidona. | |
| MX2015014590A (es) | Tratamiento de cancer con dihidropirazino-pirazinas. | |
| MX368407B (es) | Tratamiento de cancer prostatico con inhibidores de tor cinasa. | |
| WO2011100769A3 (en) | Kinase modulators for the treatment of cancer | |
| NZ707636A (en) | Ingenol-derived compounds that can be used for treating cancer | |
| IN2015KN00375A (zh) | ||
| EP2836217A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SIDE EFFECTS ASSOCIATED WITH THE ADMINISTRATION OF ANTICANCER CHEMOTHERAPEUTIC AGENTS | |
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| PH12014502464A1 (en) | Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases | |
| PH12015500306A1 (en) | Arry-520 for use in treating cancer in a patient with low aag | |
| RU2012115039A (ru) | Способ лечения хронического эндометрита | |
| UA66112U (ru) | Способ лечения злокачественных новообразований головного мозга | |
| UA88769U (uk) | Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності | |
| UA69222U (ru) | Способ рефлексотерапии больных с отдаленными последствиями черепно-мозговой травмы | |
| UA75641U (uk) | Спосіб комплексного лікування хворих з набряковими формами раку грудної залози |